ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A phase II, multicenter, randomized, controlled, open-label study of the safety, efficacy and pharmacokinetics of ABT-263 in combiantion with dose-intensive rituximab, or dose-intensive rituximab alone, in previously untreated pateints with B-cell, chronic lymphocytic leukemia (CLL)
EudraCT number 2009-012152-24
Protocol number ABT4710m
Sponsor Abbott GmbH & Co. KG, Německo
Indications Oncology
Diagnosis leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2011
Date of approval by Institute (SÚKL) 24.10.2011
Date of approval by EC 26.5.2010
Date of initiation CT in ČR
Date of ending CT in ČR 3.2.2012
Sites I. interní klinika hematoonkologie VFN a 1. LF UK, Praha
2. interní klinika - odd. klinické hematologie, FN Hradec Králové
Interní hematoonkoogická koinika FN Brno

‹‹ Back to list